Zepto Life Technology Holds Informational Panel with CMS Administrator Seema Verma and Minnesota’s 6th Congressional District U.S. Representative Tom Emmer
September 01, 2020 at 7:00 AM EDT
ST. PAUL, Min.–September 01, 2020—Zepto Life Technology hosted an informational panel with CMS Administrator Seema Verma and Minnesota’s 6th Congressional District U.S. Representative Tom Emmer at 12:00pm Monday, (CT) August 31st, 2020.
Zepto Life Technology’s CEO and founder, Yongyong Zhang, demonstrated Zepto’s latest innovative, proprietary solutions to bringing clinical sensitivity diagnostic tests to the point-of-care.
During the information exchange, the potential application of Zepto’s fully integrated POC solutions were discussed by Administrator Verma and Representative Emmer. By combining telemedicine and Zepto’s lab-on-a-chip diagnostic instruments, the resulting point-of-care product can lower time-to-treatment, reduce need for patient transport, and better patient outcome.
The meeting concluded with Administrator Verma expressing her interest for Zepto’s innovative GMR COVID-testing platforms to soon bring new valued diagnostic solutions to the public.
About Zepto Life Technology
Zepto Life Technology is an in-vitro diagnostics company with unique, accurate and multiplex-ready “lab-on-a-chip” biotechnology. The company is developing clinical solutions with Mayo Clinic, and improving patient outcomes through superior assay performance at patients’ exact points of need.
This press release may contain forward-looking statements regarding future events and the future performance of Zepto Life Technology that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management’s current beliefs and expectations. These statements include, but are not limited to, statements that relate to Zepto’s business and its future, including certain company milestones, and any statements that relate to the intent, belief, plans or expectations of Zepto or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Zepto’s existing and new product candidates may not prove safe or effective, the possibility that our applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new product candidates, if approved, may not be more effective, safer or more cost efficient than competing products, our dependence on third parties for clinical trials, manufacturing, distribution and quality control, and other risks. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
ZEPTO LIFE TECHNOLOGY, LLC® is a registered trademark of Zepto Life Technology, LLC and the Zepto logos are trademarks owned by Zepto Life Technologies, LLC. .Any other trademarks are the property of their respective owners.
© 2019 Zepto Life Technology, LLC. All Rights Reserved
Office Manager/HR Coordinator